Search PubMed⌕ Search

Biomedical subjects

J Blom

Publications and source records attributed to J Blom.

At least 145 records · Page 8Linked to original sources
PubMed1976

Evaluation of an intermittent schedule of dibromodulcitol in breast cancer.

Dibromodulcitol was administered orally on Days 1-10 every 3-4 weeks to 29 patients with metastatic breast carcinoma refractory to previous combination chemotherapy. Initial doses between 70 and 280 mg/m2/day were utilized. The dose was escalated as tolerated in subsequent cycles in individual patients. Hematosuppression was dose-limiting. At doses of greater than 200 mg/m2/day leukopenia (greater than 1000 cells/mm3) and thrombocytopenia (greater than 25,000 platelets/mm3) occurred in one of 28 cycles and two of 27 cycles respectively. In contrast, at doses of less than or equal to 200 mg/m2/day leukopenia and thrombocytopenia occurred in four of 18 cycles and five of 18 cycles respectively. Recovery of leukocytes (less than 4000 cells/mm3) and platelets (less than 100,000 platelets/mm3) by Day 29 after the start of therapy was also delayed at higher doses. Responses were observed in three of 29 evaluable patients and subjective improvement of osseous disease in one additional patient. A dose of 180 mg/m2/day X 10 Every 28 days is recommended in previously treated patients to avoid severe hematologic side effects.

Adult↗
PubMed1975

Comparison of the combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and vincristine with two dose schedules of 5-(3,3-dimethyl-1-triazino) imidazole 4-carboxamide (DTIC) in the treatment of disseminated malignant melanoma.

One hundred twenty patients with inoperable metastatic malignant melanoma were randomly allocated to treatment with either a combination of BCNU 150 mg/m2 and vincristine 2 mg/m2 given every 30 days, or one of two regimens of DTIC: 300 mg/m2/day x 6 or 100 mg/m2/8 hours x 18 given every 30 days. Eight of the 51 (16%) patients who were originally treated with the BCNU and vincristine combination had 50% or more objective tumor regression, compared to 6 out of 25 (24%) patients treated with daily injections of DTIC, and 6 out of 21 (29%) patients treated with DTIC injections every 8 hours. The median duration of response to the BCNU and vincristine combination was 60 days, and the median duration of survival from initiation of treatment was 6.5 months in the responders and 3.3 months in the nonresponders. The median duration of response was 90 and 100 days for the daily and 8-hour regimens of DTIC respectively, andthe median duration of survival from commencement of treatment was 8.5 months for the responders and 3.5 months for the nonresponders. None of the 43 patients who failed to respond to the initial treatment program or whose disease progressed after initial improvement responded to the alternate treatment regimen.

Adult↗
PubMed1975

Involvement of the central nervous system in non-Hodgkin's lymphoma.

Twenty-four patients with non-Hodgkin's lymphoma and CNS involvement are presented. There were 7 cases with diffuse histiocytic lymphoma (HL), 9 with diffuse poorly differentiated lymphocytic lymphoma (PDLL-D), of whom 6 patients were in leukemic conversion, 5 patients with nodular poorly differentiated lymphocytic lymphoma (PDLL-N), and 3 cases with undifferentiated lymphoma (UL). CNS complications were noted only in Stage IV lymphoma; the prognosis was generally poor. Histiocytic lymphoma was associated with widespread parenchymatous infiltration, whereas PDLL was usually associated with leptomeningeal seeding. The clinical course and the neuropathologic findings are discussed.

Adolescent↗
PubMed1975

Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia.

Three hundred twenty-six patients with acute myelocytic leukemia were randomly and prospectively assigned to four therapeutic regimens: cytosine arabinoside either alone or in combination with daunorubicin, 6-mercaptopurine, or 6-thioguanine. The results in 231 qualified previously untreated patients were analyzed. The combination treatments produced a significantly greater frequency of complete or partial remission than single drug therapy. Treatment with cytosine arabinoside and thioguanine led to 48% age-adjusted complete and partial responses. The median sur survival from diagnosis of all 66 evaluable patients treated with these two drugs was 18 weeks, while the median survival for those who responded to this combination was 15 months.

Adult↗
PubMed1975

Correlation between twitching motility and possession of polar fimbriae in Acinetobacter calcoaceticus.

Negatively stained preparations of 16 strains of Acinetobacter calcoaceticus were examined in the electron microscope. Five of the strains did and 11 of the strains did not exhibit twitching motility. Two of the non-twitching strains were substrains of twitching wild-type strains. All twitching strains were found to possess fimbriae with a diameter of approximately 50 A. These fimbriae were shown to be of polar origin except in one strain where, for technical reasons, the origin could not be determined with certainty. Polar fimbriae could not be demonstrated in any of the strains that did not exhibit twitching motility. The demonstration of polar fimbriae was only regularly possible during the exponential growth phase, presumably because the fimbriae are shed by the bacteria during later growth phases. During the study, methods were developed for securing exponentially growing bacteria in concentrations suited for the preparation of negatively stained cells for electron microscopy. Peritrichously arranged fimbriae with a diameter of approximately 30 A were demonstrated in nearly all strains studied, especially on cells in late growth phases. The occurrence of this kind of fimbriae was therefore not correlated with the occurrence of twitching motility.

Acinetobacter↗
PubMed1975

Examination of fimbriation of some gram-negative rods with and without twitching and gliding motility.

Negatively stained preparations of 30 different strains of gram-negative rods representing 20 different taxa were examined in the electron microscope. Thirteen of the strains studied exhibited twitching and six of the strains exhibited motility. Additionally, non-twitching substrains of two of the twitching strains and a non-gliding substrain of one of the gliding strains were examined. A variety of cultural media, preparations for negative straining and negative strains were used. It was found that all strains with twitching motility possessed fimbriae, the diameter of which was approximately 50 A in all but one strain; the fimbriae of this strain had a diameter of approximately 40 A. The fimbriae were judged to be of polar origin in all cases where the origin could be determined with certainty. On none of the strains without twitching motility could fimbriae be demonstrated. Only one of the six strains with gliding motility possessed fimbriae.

Alcaligenes↗
PubMed1973

Nonbacterial pneumonitis with multidrug antineoplastic therapy in breast carcinoma.

Seventeen patients with metastatic breast carcinoma were treated with a combination of 5-fluorouracil, methotrexate, vincristine, cyclophosphamide and prednisone. Six of the patients (35%) developed a syndrome consisting of fever, malaise, dyspnea, hypoxemia and bilateral pulmonary interstitial infiltrates from 41 to 148 days after institution of therapy. The syndrome varied from a mild to a life-threatening illness with recovery in 10 to 60 days. It is believed that these cases represent examples of methotrexate-induced pneumonitis. The high incidence of the syndrome in this patient group may be related to the concomitant administration of cyclophosphamide with methotrexate. The observations also suggest that patients with previous adrenalectomies may have pneumonitis with an especially severe and protracted course.

Adenocarcinoma↗